The State Intellectual Property Office (SIPO) of the People’s Republic of China has granted to Bionaturis and CSIC the patent entitled “Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the protein of leishmania infantum with specific immunodominant epitopes “ under the number CN 201280045285. This patent belongs to the original patent family that protects the use and application of the candidate BNT005 for the treatment and prevention of canine visceral leishmaniasis.
BNT005 is currently subject to an Evaluation and Option (E&O) agreement with an international sponsor for the exclusive worldwide license to register and commercialize this vaccine against canine leishmaniasis in all countries except Argentina and Paraguay.
At the same time, BNT005 is also subject to an exclusive license agreement for registration, development, manufacture and marketing with Biotandil for the Argentine and Paraguayan markets. Under the agreement, Bionaturis will receive 50% of the profits from the commercial exploitation of the vaccine within the territory.
For the official disclosing Click here (only in Spanish)